Real-world safety and clinical outcomes of apixaban in patients with cancer and atrial fibrillation
Lolwa S Alabdelmuhsin, Metab F Alwethairi, Dimah Alharbi, Ohoud A Almadani, Hisham A Badreldin, Lama Alfehaid · 2026
Read Real-world safety and clinical outcomes of apixaban in patients with cancer and atrial fibrillation by Lolwa S Alabdelmuhsin, Metab F Alwethairi, Dimah Alharbi, Ohoud A Almadani, Hisham A Badreldin, Lama Alfehaid (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13612253.txt.
Description
Lolwa S Alabdelmuhsin leads a six-author team reporting real-world outcomes for the blood thinner apixaban in Saudi patients with both cancer and atrial fibrillation. These patients sit between clotting and bleeding risks, and trial data in Middle Eastern populations are thin. The retrospective study covered 72 adults with active cancer or a cancer history treated at one tertiary center between August 2016 and October 2020. Events were tracked for six months after starting the drug.
Thrombotic events struck 9.7 percent of patients, including three strokes and three deep vein clots. Bleeding was far commoner, at 36.1 percent, with major bleeding in 9.7 percent. Nearly 29 percent of patients died during follow-up, chiefly from cancer. About a quarter stopped apixaban for clinical reasons such as bleeding or breakthrough clots. The authors read the numbers as a portrait of how precarious anticoagulation is in this group. They argue for close monitoring plus prospective studies.
Catalog record
| CREATOR | Lolwa S Alabdelmuhsin, Metab F Alwethairi, Dimah Alharbi, Ohoud A Almadani, Hisham A Badreldin, Lama Alfehaid |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |